Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2133.1998.02526.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful treatment of recurrent refractory Kaposi's sarcoma in AIDS: a case report.
Front Oncol
December 2024
The Second Infectious Disease Department, Xixi Hospital of Hangzhou, Hangzhou, China.
Article Synopsis
- Kaposi's sarcoma (KS) is a soft tissue lesion linked to HHV-8 infection, often seen in immunocompromised patients, especially those with AIDS, and has a high mortality rate.
- A case report details a patient with AIDS-KS who relapsed after initial chemotherapy, but achieved complete remission with a PD-1 inhibitor, indicating its effectiveness in treatment.
- The PD-1 inhibitor was well-tolerated, improved the patient's immune system, and suggests a promising approach for managing AIDS-KS.
A KSHV RNA-binding protein promotes FOS to inhibit nuclease AEN and transactivate RGS2 for AKT phosphorylation.
mBio
January 2025
Tumor Virus RNA Biology Section, HIV Dynamics and Replication Program, Center for Cancer Research, NCI/NIH, Frederick, Maryland, USA.
Kaposi's sarcoma-associated herpesvirus (KSHV) encodes an RNA-binding protein ORF57 in lytic infection. Using an optimized CLIP-seq in this report, we identified ORF57-bound transcripts from 544 host protein-coding genes. By comparing with the RNA-seq profiles from BCBL-1 cells with latent and lytic KSHV infection and from HEK293T cells with and without ORF57 expression, we identified FOS RNA as one of the major ORF57-specific RNA targets.
View Article and Find Full Text PDFDevelopment of KSHV vaccine platforms and chimeric MHV68-K-K8.1 glycoprotein for evaluating the immunogenicity and efficacy of KSHV vaccine candidates.
mBio
December 2024
Department of Cancer Biology and Infection Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Article Synopsis
- Kaposi's sarcoma-associated herpesvirus (KSHV) is responsible for diseases like Kaposi's Sarcoma and has a high prevalence in sub-Saharan Africa, making vaccine development critical, but existing challenges include the absence of viable animal models for KSHV infection.
- The study created a chimeric mouse virus (MHV68-K-K8.1) to mimic KSHV infection and tested two K8.1 vaccines (mRNA-LNP and Ferritin nanoparticles) which successfully stimulated immune responses in mice.
- Results showed that mice vaccinated with K8.1 mRNA LNP vaccines had reduced viral levels and reactivation rates of the surrogate virus, indicating the potential effectiveness of these
Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary.
Pathol Oncol Res
September 2024
Division of Hematology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary.
Castleman disease is a rare and atypical lymphoproliferative disorder characterized by diverse clinical manifestations. It has both unicentric and multicentric forms, the latter with further subdivisions, i.e.
View Article and Find Full Text PDFAn Unusual Case of HHV-8 Negative, Idiopathic, Multicentric Castleman Disease Following Chronic Lymphocytic Leukaemia.
Eur J Case Rep Intern Med
August 2024
Department of Hematology, CHU UCL Yvoir, Namur, Belgium.
Background: Castleman disease is a rare condition characterised by polytypic lymphocytes proliferation and lymphadenopathy generally with a benign course. Whereas high grade lymphoma (Richter syndrome) is a classical complication seen in chronic lymphocytic leukaemia with a poor outcome, benign conditions mimicking this entity are infrequent.
Case Description: We describe the case of an 81-year-old Caucasian male who developed a human herpesvirus-8 (HHV-8)-negative, idiopathic multicentric Castleman disease (iMCD) following a treated Binet C chronic lymphocytic leukaemia (CLL).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!